R&D channel feed

Lit­tle Cona­tus' No­var­tis-part­nered liv­er drug suf­fers third straight de­feat, but CEO Men­to is still hold­ing out hope

7 years ago
People

Hard-charg­ing GSK re­search chief Hal Bar­ron touts im­proved an­ti-BC­MA da­ta, aim­ing for fast ap­pli­ca­tions

7 years ago

$757M and 5 years lat­er, Cel­gene aban­doned a biotech part­ner, trig­ger­ing lay­offs

7 years ago
People

Brex­it who? Record in­vest­ment last year fu­els big spike in reg­is­tered UK biotech firms

7 years ago
Financing

Bio­gen's Alzheimer's drug ad­u­canum­ab im­plodes in a PhI­II dis­as­ter — putting them at a per­ilous cross­roads

7 years ago

NASH drug in hand, Mer­ck forges ahead with 2-year ex­ten­sion of NGM Bio col­lab­o­ra­tion deal

7 years ago
Pharma

Glax­o­SmithK­line sets its sights on a quick leap in­to the big PD-1/L1 game — will any­one no­tice?

7 years ago

Pfiz­er, Mer­ck KGaA throw in the tow­el on an­oth­er Baven­cio PhI­II as once bright hopes shriv­el fast

7 years ago

Roche, Ab­b­Vie forced to slam brakes on myelo­ma stud­ies of star drug Ven­clex­ta af­ter re­searchers flag high­er risk of death

7 years ago

Vivek Ra­maswamy’s Urovant claims a big win in PhI­II — but ques­tions linger about a cheap gener­ic and their brand­ed ri­val

7 years ago

Amarin posts an­oth­er round of promis­ing car­dio out­comes da­ta for Vas­cepa. Cue more M&A chat­ter and ar­gu­ment

7 years ago

Al­ler­gy Ther­a­peu­tic­s' im­munother­a­py prospect tar­nished af­ter birch vac­cine flops in PhI­II

7 years ago

Aer­pio shares tum­ble as lead eye drug trips up in mid-stage di­a­bet­ic retinopa­thy study

7 years ago

Lit­tle Der­mi­ra’s shares zoom up on promis­ing PhI­Ib atopic der­mati­tis da­ta — but the road ahead is ul­tra risky and flanked by heav­i­ly armed gi­ants

7 years ago

Spec­trum yanks mar­ket­ing ap­pli­ca­tion for Neu­las­ta ri­val af­ter FDA de­mands more da­ta

7 years ago

The world's top 10 block­busters — and what they tell us about R&D trends

7 years ago

Deer­field takes trans­la­tion­al part­ner­ship mod­el to Har­vard with $100M deal

7 years ago
Startups

Scan­dal-prone Sub­sys mak­er In­sys falls as au­di­tor flags go­ing con­cern doubt

7 years ago

Cel­gene's chemother­a­py Abrax­ane stum­bles in piv­otal pan­cre­at­ic can­cer study

7 years ago

GeNeu­ro touts a mixed set of ex­ten­sion da­ta in a shot at sal­vaging their failed mid-stage MS drug

7 years ago

With Al­im­ta patent cliff loom­ing, Lil­ly plots stronger foothold in front­line NSCLC with Cyra­mza

7 years ago

Zaf­gen's sec­ond try at Prad­er-Willi syn­drome trig­gers an­oth­er safe­ty alarm in pre­clin­i­cal tox study

7 years ago

Ear­ly da­ta snap­shots of Ax­o­van­t's gene ther­a­pies for Parkin­son's, Tay Sachs ap­pear promis­ing

7 years ago
Cell/Gene Tx

Years af­ter it was OK'd, AM­AG's drug for pre­vent­ing preterm births fails bad­ly in long-await­ed con­fir­ma­to­ry tri­al

7 years ago
First page Previous page 250251252253254255256 Next page Last page
A service from the Financial Times